Clinical Trial Goal
To find out if VSV-hIFNbeta-NIS, alone or with other drugs, is safe and works well to treat AML, multiple myeloma, or T-cell lymphoma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following diseases that has relapsed or is refractory:
- AML
- Anaplastic large cell lymphoma (ALCL)
- Angioimmunoblastic T-cell lymphoma (AITL)
- B-cell non-Hodgkin lymphoma (NHL)
- Cutaneous T-cell lymphoma (CTCL)
- MDS
- Multiple myeloma
- Mycosis fungoides
- Peripheral T-cell lymphoma (PTCL)
- Do not have acute promylelocytic leukemia
- Do not have cancer in your brain or spinal cord
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Cemiplimab is a monoclonal antibody that target PD-1 on certain cells.
Ruxolitinib is a small molecule inhibitor that blocks JAK1 and JAK2 in certain cells.
Ipilimumab is a checkpoint inhibitor that targets CTLA-4 on certain cells.
VSV-hIFNbeta-NIS is a virus that has been treated in a lab. Doctors think this virus can find and kill cancer cells.
In this trial, you’ll be placed in 1 of 4 groups based on your diagnosis and what the clinical trial doctors thinks is best for your health. You'll be told what group you're in:
Ruxolitinib is a small molecule inhibitor that blocks JAK1 and JAK2 in certain cells.
Ipilimumab is a checkpoint inhibitor that targets CTLA-4 on certain cells.
VSV-hIFNbeta-NIS is a virus that has been treated in a lab. Doctors think this virus can find and kill cancer cells.
In this trial, you’ll be placed in 1 of 4 groups based on your diagnosis and what the clinical trial doctors thinks is best for your health. You'll be told what group you're in:
- Group 1 – VSV-hIFNbeta-NIS
- Group 2 - VSV-hIFNbeta-NIS plus ipilimumab and cemiplimab
- Group 3 - VSV-hIFNbeta-NIS plus ruxolitinib, ipilimumab and cemiplimab
You’ll get:
- Cemiplimab - Group 2 and 3 only - Given as an intravenous (IV) infusion 1 time
- Ipilimumab - Group 2 and 3 only - Given as an IV infusion 1 time
- VSV-hIFNbeta-NIS – Given as an IV infusion 1 time. The infusion takes about 30 minutes
You'll have scans to see how well the treatment is working. After you finish treatment, the clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved VSV-hIFNbeta-NIS. All of the other drugs used have been approved.
Locations
Mayo Clinic in ArizonaRECRUITING
Scottsdale, Arizona
Clinical Trials Referral Office, 855-776-0015, mayocliniccancerstudies@mayo.edu
Mayo Clinic in RochesterRECRUITING
Rochester, Minnesota
Clinical Trials Referral Office, 855-776-0015, mayocliniccancerstudies@mayo.edu
Sponsors
collaborator: National Cancer Institute (NCI), lead: Mayo Clinic

